Compare BioNTech SE - ADR (BNTX) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs ProShares UltraPro S&P500 — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while ProShares UltraPro S&P500 trades at $145.5. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | UPRO | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $119.34 | $150.93 |
52-Week Low | $83.89 | $89.29 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
UPRO is trading at $142.72, down 2.35% on the day, with technical indicators showing a bullish bias as moving averages signal strength while oscillators remain neutral. The stock faces immediate resistance at $145 and support at $141. Recent market sentiment reflects cautious optimism around S&P 500 performance, with analysts projecting potential index gains to 8,000 by year-end despite concerns about AI fatigue and elevated valuations.
The outlook for UPRO remains tied to broader market momentum, with earnings season potentially providing the next catalyst. Key risks include market volatility from Fed policy uncertainty and stretched valuations, while institutional positioning suggests continued confidence in large-cap US equities as the primary driver of returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
